The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its legacy within the broader market now triggers questions about future yields . Copycat versions are diminishing patent protection , causing worries that investing in companies heavily reliant to Viagra's previous position could be a problematic